Bicara Therapeutics Inc. has provided an update on the development of ficerafusp alfa (FICERA), its lead bifunctional antibody targeting EGFR and TGF-β pathways, for the treatment of first-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma (HNSCC). The company announced the initiation of a pivotal study with FICERA at a 1500 mg weekly dose, aiming to support potential accelerated approval. The presentation highlights the challenges of treating HPV-negative HNSCC, which constitutes 80-90% of HNSCC cases in the recurrent/metastatic setting and is associated with worse prognosis compared to HPV-positive disease. Bicara is also exploring FICERA's potential in other solid tumors, including metastatic colorectal cancer, as part of its broader development strategy. Interim analysis for the ongoing study is planned for mid-2027. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.